FAKTOR-OPTIONSSCHEIN - ZEALAND PHARMA | Market Closed - Börse Stuttgart 11:22:02 2024-06-07 am EDT | ||
| 7 EUR | +0.57% |
|
| Current month | -9.56% | ||
| 1 month | -14.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-07 | 7 | +0.57% |
| 24-06-06 | 6.96 | -19.54% |
| 24-06-05 | 8.65 | +10.19% |
| 24-06-04 | 7.85 | +5.37% |
| 24-06-03 | 7.45 | -3.75% |
Delayed Quote Börse Stuttgart
Last update June 07, 2024 at 11:22 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | MG1VGQ |
| ISIN | DE000MG1VGQ4 |
| Date issued | 2024-04-08 |
| Strike | 868 kr |
| Maturity | Unlimited |
| Parity | 4.05 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.14 € |
|---|---|
| Lowest since issue | 6.96 € |
| Spread | 0.55 € |
| Spread % | 7.38% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
650
DKK
Average target price
785.6
DKK
Spread / Average Target
+20.86%
- Stock Market
- Certificates
- Certificat
